Shares Fall Over 9% as Biotech Giant Transitions Away from Pandemic-Era Vaccine Sales
BioNTech (BNTX), the pioneering biotechnology firm behind the widely-used COVID-19 vaccine developed in partnership with Pfizer, announced a significant downturn in revenue and earnings for 2023. The German-based company’s shift towards cancer drug development led to a reported plunge in revenue by over three-quarters compared to the previous year, with net profit plummeting by 90%.
Following the report, BioNTech shares experienced a sharp decline of over 9%. The company anticipates 2024 revenues to range between 2.5 billion to 3.1 billion euros, contingent upon regulatory developments and the ongoing uptake of COVID-19 vaccines. This projection marks a notable reduction from their initial forecast of approximately 3 billion euros for the same period.
BioNTech outlined its strategic focus on oncology, aiming for its inaugural oncology launch by 2026 and targeting ten indication approvals by 2030. Despite the revenue setback, the company anticipates a return to revenue growth by 2025, as it navigates the declining trajectory of its COVID-19 vaccine business and ramps up investments in oncology.
You might like this report:Macy’s Opens Books to Potential Buyers, Shares Surge
